M&A buzz: ViroPharma could go for $60 per share in buyout

The rare-disease drug specialist ViroPharma ($VPHM) has been generating buyout buzz all week after reports that the company brought on the services of Goldman Sachs to hunt for potential acquisition offers. Sanofi ($SNY) and Shire ($SHPG), two major players in the rare disease arena, have reportedly taken an interest in ViroPharma, Bloomberg reports. And JMP Group thinks that the company, which closed at $40 per share earlier this week, could be sold for $60 a share. Article

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.